

Therapeutic Class Ranking (Top 100 Ranked by Ingredient Cost)
Prescriptions filled from 01/2006 through 12/2006 compared to 01/2007 through 12/2007
Outside Quebec

| GPI | Therapeutic Class Name | Common Indications | # Claims | | % of Total | | Ing Cost | | % of Total Ing | | Avg Ing Cost/Claim | | % Change in |
|--------|--|--------------------------------|----------|------|------------|-------|----------|------|----------------|-------|--------------------|-------------|------------------|
| | | | Rank | | Claims | | Rank | | Cost | | Avg | | |
| | | | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | Ing Cost / Claim |
| 394000 | HMG CoA Reductase Inhibitors | HIGH CHOLESTEROL | 1 | 1 | 3.98% | 4.24% | 1 | 1 | 8.74% | 9.03% | \$ 115.47 | \$ 113.60 | -1.63% |
| 492700 | Proton Pump Inhibitors | ULCER / REFLUX | 2 | 2 | 3.57% | 3.70% | 2 | 2 | 7.72% | 7.34% | \$ 113.60 | \$ 105.66 | -6.99% |
| 581600 | Selective Serotonin Reuptake Inhibitors (SSRIs) | DEPRESSION | 3 | 3 | 3.26% | 3.29% | 4 | 3 | 3.53% | 3.54% | \$ 56.90 | \$ 57.41 | 0.90% |
| 361000 | ACE Inhibitors | HIGH BLOOD PRESSURE | 4 | 4 | 3.22% | 3.27% | 3 | 4 | 3.97% | 3.34% | \$ 64.73 | \$ 54.44 | -15.89% |
| 340000 | Calcium Channel Blockers | HIGH BLOOD PRESSURE | 13 | 12 | 1.94% | 2.01% | 5 | 5 | 3.19% | 3.25% | \$ 86.41 | \$ 86.20 | -0.24% |
| 442099 | Adrenergic Combinations | ASTHMA / COPD | 23 | 23 | 1.14% | 1.14% | 8 | 6 | 2.34% | 2.41% | \$ 107.62 | \$ 113.20 | 5.19% |
| 651000 | Opioid Agonists | PAIN, NARCOTIC ANALGESICS | 19 | 11 | 1.39% | 2.03% | 9 | 7 | 2.08% | 2.06% | \$ 78.76 | \$ 53.95 | -31.51% |
| 525050 | Tumor Necrosis Factor Alpha Blockers | RHEUMATOID ARTHRITIS | 234 | 219 | 0.02% | 0.03% | 14 | 8 | 1.59% | 2.03% | \$ 3,682.46 | \$ 3,777.70 | 2.59% |
| 581800 | Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) | DEPRESSION | 17 | 18 | 1.75% | 1.75% | 6 | 9 | 2.71% | 2.02% | \$ 81.62 | \$ 61.63 | -24.49% |
| 662900 | Soluble Tumor Necrosis Factor Receptor Agents | RHEUMATOID ARTHRITIS | 184 | 178 | 0.05% | 0.06% | 13 | 10 | 1.69% | 1.99% | \$ 1,634.01 | \$ 1,792.61 | 9.71% |
| 361500 | Angiotensin II Receptor Antagonists | HIGH BLOOD PRESSURE | 22 | 21 | 1.23% | 1.36% | 10 | 11 | 1.82% | 1.98% | \$ 77.97 | \$ 77.94 | -0.04% |
| 999000 | Not Classified | DIABETES | 5 | 16 | 2.93% | 1.75% | 7 | 12 | 2.48% | 1.78% | \$ 44.47 | \$ 54.02 | 21.49% |
| 271040 | Human Insulin | DIABETES | 32 | 25 | 0.90% | 1.05% | 18 | 13 | 1.20% | 1.63% | \$ 70.37 | \$ 82.52 | 17.26% |
| 674060 | Selective Serotonin Agonists 5-HT(1) | MIGRAINE | 39 | 42 | 0.63% | 0.62% | 12 | 14 | 1.73% | 1.62% | \$ 143.77 | \$ 138.34 | -3.77% |
| 276070 | Thiazolidinediones | DIABETES | 51 | 52 | 0.49% | 0.47% | 11 | 15 | 1.75% | 1.60% | \$ 186.45 | \$ 182.68 | -2.03% |
| 624030 | Multiple Sclerosis Agents - Interferons | MULTIPLE SCLEROSIS | 190 | 190 | 0.05% | 0.05% | 15 | 16 | 1.54% | 1.53% | \$ 1,561.73 | \$ 1,606.06 | 2.84% |
| 726000 | Anticonvulsants - Misc. | NEUROLOGICAL DISORDERS | 34 | 33 | 0.81% | 0.91% | 16 | 17 | 1.34% | 1.52% | \$ 87.54 | \$ 89.39 | 2.11% |
| 259900 | Combination Contraceptives - Oral | BIRTH CONTROL | 10 | 10 | 2.13% | 2.09% | 17 | 18 | 1.27% | 1.26% | \$ 31.44 | \$ 32.14 | 2.24% |
| 300420 | Bisphosphonates | OSTEOPOROSIS | 33 | 34 | 0.90% | 0.89% | 20 | 19 | 1.18% | 1.15% | \$ 69.05 | \$ 68.68 | -0.54% |
| 422000 | Nasal Steroids | ALLERGY | 14 | 15 | 1.90% | 1.84% | 21 | 20 | 1.11% | 1.11% | \$ 30.78 | \$ 31.99 | 3.94% |
| 444000 | Steroid Inhalants | ASTHMA / COPD | 25 | 28 | 1.09% | 0.99% | 19 | 21 | 1.18% | 1.08% | \$ 56.57 | \$ 58.08 | 2.66% |
| 661000 | Nonsteroidal Anti-inflammatory Agents (NSAIDs) | NSAIDS - PAIN AND INFLAMMATION | 6 | 5 | 2.78% | 2.67% | 22 | 22 | 1.11% | 1.01% | \$ 20.99 | \$ 20.24 | -3.55% |
| 661005 | Cyclooxygenase 2 (COX-2) Inhibitors | NSAIDS - PAIN AND INFLAMMATION | 44 | 36 | 0.58% | 0.74% | 26 | 23 | 0.87% | 1.00% | \$ 78.65 | \$ 71.62 | -8.93% |
| 369940 | Angiotensin II Receptor Antagonists & Thiazides | HIGH BLOOD PRESSURE | 45 | 39 | 0.58% | 0.66% | 27 | 24 | 0.86% | 0.98% | \$ 78.58 | \$ 79.36 | 0.99% |
| 851580 | Thienopyridine Derivatives | CARDIOVASCULAR DISEASE | 62 | 61 | 0.39% | 0.40% | 23 | 25 | 0.92% | 0.92% | \$ 123.18 | \$ 124.29 | 0.90% |
| 445050 | Leukotriene Receptor Antagonists | ASTHMA / COPD | 55 | 53 | 0.44% | 0.47% | 25 | 26 | 0.88% | 0.92% | \$ 104.78 | \$ 105.07 | 0.28% |
| 035000 | Clarithromycin | ANTIBIOTICS / ANTI-INFECTIVES | 27 | 27 | 1.01% | 1.00% | 24 | 27 | 0.90% | 0.87% | \$ 46.73 | \$ 46.53 | -0.41% |
| 614000 | Stimulants - Misc. | ATTENTION DEFICIT DISORDER | 52 | 50 | 0.49% | 0.48% | 29 | 28 | 0.82% | 0.82% | \$ 88.86 | \$ 90.31 | 1.63% |
| 259920 | Triphasic Contraceptives - Oral | BIRTH CONTROL | 20 | 22 | 1.39% | 1.31% | 28 | 29 | 0.83% | 0.78% | \$ 31.57 | \$ 31.90 | 1.05% |
| 124050 | Herpes Agents - Purine Analogues | ANTIBIOTICS / ANTI-INFECTIVES | 65 | 58 | 0.39% | 0.42% | 32 | 30 | 0.70% | 0.77% | \$ 94.78 | \$ 98.44 | 3.85% |
| 393000 | Intestinal Cholesterol Absorption Inhibitors | HIGH CHOLESTEROL | 78 | 70 | 0.28% | 0.36% | 36 | 31 | 0.59% | 0.76% | \$ 110.74 | \$ 112.32 | 1.43% |
| 050000 | Fluoroquinolones | ANTIBIOTICS / ANTI-INFECTIVES | 24 | 24 | 1.10% | 1.11% | 30 | 32 | 0.71% | 0.71% | \$ 33.66 | \$ 34.24 | 1.72% |
| 824015 | Granulocyte Colony-Stimulating Factors (G-CSF) | BLOOD DISORDERS | 256 | 244 | 0.02% | 0.02% | 37 | 33 | 0.58% | 0.70% | \$ 1,866.67 | \$ 1,913.61 | 2.51% |
| 332000 | Beta Blockers Cardio-Selective | HIGH BLOOD PRESSURE | 15 | 14 | 1.89% | 1.93% | 31 | 34 | 0.70% | 0.67% | \$ 19.56 | \$ 18.35 | -6.20% |
| 941000 | Diagnostic Reagents | DIABETES | 106 | 68 | 0.19% | 0.37% | 63 | 35 | 0.33% | 0.63% | \$ 90.20 | \$ 92.02 | 2.02% |
| 905500 | Corticosteroids - Topical | SKIN CONDITIONS | 9 | 8 | 2.25% | 2.18% | 33 | 36 | 0.65% | 0.63% | \$ 15.25 | \$ 15.39 | 0.90% |
| 272500 | Biguanides | DIABETES | 21 | 20 | 1.32% | 1.41% | 35 | 37 | 0.59% | 0.63% | \$ 23.62 | \$ 23.78 | 0.67% |
| 525000 | Inflammatory Bowel Agents | INFLAMMATORY BOWEL DISEASE | 93 | 95 | 0.24% | 0.23% | 34 | 38 | 0.61% | 0.61% | \$ 135.35 | \$ 138.70 | 2.48% |
| 662700 | Anti-TNF-alpha - Monoclonal Antibodies | RHEUMATOID ARTHRITIS | 285 | 251 | 0.01% | 0.02% | 65 | 39 | 0.31% | 0.58% | \$ 1,601.04 | \$ 1,769.28 | 10.51% |
| 171000 | Viral Vaccines | PREVENTATIVE VACCINES | 82 | 64 | 0.27% | 0.39% | 84 | 40 | 0.24% | 0.57% | \$ 46.28 | \$ 78.18 | 68.95% |
| 403040 | Selective cGMP Phosphodiesterase Type 5 Inhibitors | ERECTILE DYSFUNCTION | 85 | 81 | 0.27% | 0.30% | 44 | 41 | 0.48% | 0.53% | \$ 94.85 | \$ 96.01 | 1.22% |
| 591570 | Thienbenzodiazepines | ANTIPSYCHOTIC | 103 | 105 | 0.20% | 0.20% | 38 | 42 | 0.56% | 0.53% | \$ 147.55 | \$ 143.33 | -2.86% |
| 624000 | Multiple Sclerosis Agents | MULTIPLE SCLEROSIS | 243 | 241 | 0.02% | 0.02% | 43 | 43 | 0.50% | 0.52% | \$ 1,322.93 | \$ 1,339.32 | 1.24% |
| 492000 | H-2 Antagonists | ULCER / REFLUX | 36 | 37 | 0.73% | 0.69% | 39 | 44 | 0.55% | 0.51% | \$ 39.25 | \$ 39.11 | -0.35% |
| 602040 | Non-Benzodiazepine - GABA-Receptor Modulators | SEDATIVE / HYPNOTIC | 28 | 26 | 1.00% | 1.05% | 42 | 45 | 0.51% | 0.50% | \$ 26.49 | \$ 25.50 | -3.73% |
| 442010 | Beta Adrenergics | ASTHMA / COPD | 12 | 13 | 2.09% | 2.00% | 40 | 46 | 0.53% | 0.48% | \$ 13.27 | \$ 12.86 | -3.09% |
| 121099 | Antiretroviral Combinations | HIV / AIDS | 230 | 213 | 0.02% | 0.03% | 59 | 47 | 0.37% | 0.47% | \$ 796.30 | \$ 828.68 | 4.07% |
| 300620 | Ovulation Stimulants-Gonadotropins | INFERTILITY | 191 | 186 | 0.05% | 0.05% | 50 | 48 | 0.41% | 0.45% | \$ 420.73 | \$ 442.29 | 5.12% |
| 591530 | Dibenzothiazepines | ANTIPSYCHOTIC | 71 | 65 | 0.34% | 0.39% | 56 | 49 | 0.38% | 0.44% | \$ 59.71 | \$ 60.77 | 1.78% |
| 389000 | Anaphylaxis Therapy Agents | ALLERGY | 115 | 111 | 0.16% | 0.17% | 49 | 50 | 0.42% | 0.43% | \$ 133.82 | \$ 136.57 | 2.06% |
| 540000 | Urinary Antispasmodics | KIDNEY / BLADDER DISEASE | 84 | 85 | 0.27% | 0.28% | 54 | 51 | 0.39% | 0.42% | \$ 77.46 | \$ 80.73 | 4.22% |
| 369918 | ACE Inhibitors & Thiazide/Thiazide-Like | HIGH BLOOD PRESSURE | 79 | 74 | 0.28% | 0.33% | 60 | 52 | 0.37% | 0.42% | \$ 69.58 | \$ 67.47 | -3.02% |
| 215340 | Antineoplastic - Tyrosine Kinase Inhibitors | ANTICANCER | 323 | 306 | 0.01% | 0.01% | 48 | 53 | 0.42% | 0.41% | \$ 4,068.39 | \$ 3,361.86 | -17.37% |
| 171099 | Viral Vaccine Combinations | PREVENTATIVE VACCINES | 63 | 59 | 0.39% | 0.40% | 51 | 54 | 0.41% | 0.41% | \$ 54.81 | \$ 54.18 | -1.16% |
| 214050 | LHRH Analogs | ANTICANCER | 200 | 198 | 0.04% | 0.04% | 47 | 55 | 0.43% | 0.40% | \$ 550.96 | \$ 553.80 | 0.52% |
| 583000 | Antidepressants - Misc. | DEPRESSION | 46 | 44 | 0.55% | 0.61% | 52 | 56 | 0.41% | 0.40% | \$ 38.84 | \$ 34.82 | -10.35% |
| 034000 | Azithromycin | ANTIBIOTICS / ANTI-INFECTIVES | 26 | 29 | 1.07% | 0.97% | 41 | 57 | 0.52% | 0.39% | \$ 25.62 | \$ 21.51 | -16.05% |

| GPI | Therapeutic Class Name | Common Indications | # Claims Rank | | % of Total Claims | | Ing Cost Rank | | % of Total Ing Cost | | Avg Ing Cost/Claim | | % Change in Avg | |
|--|--|---------------------------------------|---------------|------|-------------------|-------|---------------|------|---------------------|---------------|--------------------|-----------------|-----------------|--------------|
| | | | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | Ing Cost /Claim | |
| 392000 | Fibric Acid Derivatives | HIGH CHOLESTEROL | 75 | 80 | 0.31% | 0.30% | 46 | 58 | 0.46% | 0.39% | \$ 77.15 | \$ 68.42 | -11.32% | |
| 441000 | Bronchodilators - Anticholinergics | ASTHMA / COPD | 100 | 94 | 0.21% | 0.24% | 64 | 59 | 0.33% | 0.38% | \$ 83.22 | \$ 84.54 | 1.58% | |
| 040000 | Tetracyclines | ANTIBIOTICS / ANTI-INFECTIVES | 50 | 51 | 0.50% | 0.48% | 57 | 60 | 0.38% | 0.36% | \$ 39.79 | \$ 40.04 | 0.62% | |
| 661099 | Nonsteroidal Anti-inflammatory Agent Combinations | NSAIDS - PAIN AND INFLAMMATION | 61 | 71 | 0.39% | 0.35% | 58 | 61 | 0.38% | 0.34% | \$ 50.00 | \$ 51.07 | 2.14% | |
| 214028 | Aromatase Inhibitors | ANTICANCER | 174 | 167 | 0.07% | 0.08% | 72 | 62 | 0.29% | 0.33% | \$ 230.13 | \$ 234.38 | 1.85% | |
| 994030 | Inosine Monophosphate Dehydrogenase Inhibitors | ORGAN TRANSPLANT | 222 | 214 | 0.03% | 0.03% | 67 | 63 | 0.31% | 0.33% | \$ 588.85 | \$ 584.32 | -0.77% | |
| 129950 | Nucleoside Analog & Interferon Combinations | ANTIBIOTICS / ANTI-INFECTIVES | 261 | 272 | 0.01% | 0.01% | 62 | 64 | 0.35% | 0.33% | \$ 1,228.80 | \$ 1,376.67 | 12.03% | |
| 022000 | Cephalosporins - 2nd Generation | ANTIBIOTICS / ANTI-INFECTIVES | 43 | 49 | 0.59% | 0.51% | 53 | 65 | 0.40% | 0.32% | \$ 35.69 | \$ 33.54 | -6.02% | |
| 824010 | Erythropoietins | BLOOD DISORDERS | 245 | 257 | 0.02% | 0.02% | 45 | 66 | 0.48% | 0.31% | \$ 1,282.90 | \$ 1,087.74 | -15.21% | |
| 612535 | Fat Absorption Decreasing Agents | WEIGHT LOSS | 134 | 151 | 0.12% | 0.09% | 55 | 67 | 0.39% | 0.30% | \$ 168.38 | \$ 170.46 | 1.23% | |
| 659910 | Codeine Combinations | PAIN, NARCOTIC ANALGESICS | 8 | 9 | 2.28% | 2.15% | 68 | 68 | 0.31% | 0.30% | \$ 7.08 | \$ 7.37 | 4.14% | |
| 613540 | ADHD Agent - Selective Norepinephrine Reuptake Inhibitor | ATTENTION DEFICIT DISORDER | 162 | 150 | 0.08% | 0.10% | 81 | 69 | 0.25% | 0.30% | \$ 158.41 | \$ 163.76 | 3.38% | |
| 415500 | Antihistamines - Non-Sedating | ALLERGY | 56 | 55 | 0.43% | 0.44% | 71 | 70 | 0.29% | 0.29% | \$ 35.61 | \$ 35.93 | 0.89% | |
| 272000 | Sulfonylureas | DIABETES | 38 | 38 | 0.66% | 0.66% | 73 | 71 | 0.29% | 0.29% | \$ 23.04 | \$ 23.72 | 2.93% | |
| 231000 | Androgens | HORMONE REPLACEMENT | 129 | 133 | 0.13% | 0.12% | 70 | 72 | 0.30% | 0.29% | \$ 119.89 | \$ 123.19 | 2.75% | |
| 279980 | Thiazolidinedione-Biguanide Combinations | DIABETES | 177 | 166 | 0.06% | 0.08% | 90 | 73 | 0.23% | 0.29% | \$ 197.74 | \$ 199.69 | 0.99% | |
| 900500 | Acne Products | ACNE | 58 | 63 | 0.41% | 0.39% | 61 | 74 | 0.35% | 0.29% | \$ 44.86 | \$ 39.23 | -12.53% | |
| 831010 | Low Molecular Weight Heparins | CARDIOVASCULAR DISEASE | 211 | 194 | 0.03% | 0.04% | 105 | 75 | 0.19% | 0.28% | \$ 293.53 | \$ 330.36 | 12.55% | |
| 902505 | Antipsoriatics - Systemic | PSORIASIS | 263 | 262 | 0.01% | 0.01% | 69 | 76 | 0.30% | 0.27% | \$ 1,099.39 | \$ 980.14 | -10.85% | |
| 249915 | Estrogen & Antiandrogen | HORMONE REPLACEMENT | 97 | 100 | 0.23% | 0.21% | 93 | 77 | 0.22% | 0.27% | \$ 51.78 | \$ 68.56 | 32.41% | |
| 301700 | Somatostatic Agents | ENDOCRINE / METABOLIC DISORDERS | 311 | 296 | 0.01% | 0.01% | 96 | 78 | 0.22% | 0.27% | \$ 1,729.56 | \$ 1,871.71 | 8.22% | |
| 240000 | Estrogens | HORMONE REPLACEMENT | 37 | 40 | 0.73% | 0.65% | 74 | 79 | 0.29% | 0.26% | \$ 20.59 | \$ 21.44 | 4.10% | |
| 620510 | Cholinomimetics - ACHE Inhibitors | ALZHEIMER DISEASE | 117 | 115 | 0.16% | 0.17% | 77 | 80 | 0.25% | 0.26% | \$ 83.26 | \$ 82.22 | -1.26% | |
| 281000 | Thyroid Hormones | THYROID DISORDERS | 11 | 7 | 2.12% | 2.19% | 85 | 81 | 0.24% | 0.25% | \$ 5.89 | \$ 6.05 | 2.84% | |
| 900599 | Acne Combinations | ACNE | 53 | 56 | 0.45% | 0.43% | 79 | 82 | 0.25% | 0.24% | \$ 28.95 | \$ 30.12 | 4.06% | |
| 260000 | Progestins | HORMONE REPLACEMENT | 72 | 77 | 0.34% | 0.32% | 83 | 83 | 0.24% | 0.24% | \$ 37.31 | \$ 39.98 | 7.16% | |
| 213000 | Antimetabolites | ANTICANCER | 105 | 104 | 0.20% | 0.20% | 86 | 84 | 0.24% | 0.24% | \$ 63.42 | \$ 63.90 | 0.75% | |
| 994040 | Macrolide Immunosuppressants | ORGAN TRANSPLANT | 236 | 235 | 0.02% | 0.02% | 80 | 85 | 0.25% | 0.23% | \$ 580.26 | \$ 542.33 | -6.54% | |
| 114070 | Triazoles | ANTIBIOTICS / ANTI-INFECTIVES | 67 | 69 | 0.37% | 0.36% | 87 | 86 | 0.24% | 0.23% | \$ 33.81 | \$ 33.74 | -0.22% | |
| 659900 | Opioid Combinations | PAIN, NARCOTIC ANALGESICS | 30 | 30 | 0.93% | 0.95% | 76 | 87 | 0.28% | 0.23% | \$ 15.88 | \$ 12.77 | -19.63% | |
| 012000 | Aminopenicillins | ANTIBIOTICS / ANTI-INFECTIVES | 7 | 6 | 2.47% | 2.33% | 89 | 88 | 0.23% | 0.22% | \$ 4.92 | \$ 5.04 | 2.59% | |
| 905599 | Topical Steroid Combinations | SKIN CONDITIONS | 111 | 109 | 0.17% | 0.17% | 91 | 89 | 0.23% | 0.22% | \$ 71.15 | \$ 67.32 | -5.38% | |
| 863300 | Prostaglandins - Ophthalmic | EYE DISEASE, GLAUCOMA | 88 | 89 | 0.26% | 0.26% | 97 | 90 | 0.21% | 0.22% | \$ 42.65 | \$ 44.64 | 4.66% | |
| 751000 | Central Muscle Relaxants | MUSCLE RELAXANT | 47 | 46 | 0.54% | 0.55% | 95 | 91 | 0.22% | 0.22% | \$ 21.55 | \$ 21.22 | -1.53% | |
| 868070 | Ophthalmics Misc. - Other | EYE DISEASE, MISC | 249 | 255 | 0.02% | 0.02% | 78 | 92 | 0.25% | 0.22% | \$ 705.56 | \$ 726.46 | 2.96% | |
| 590700 | Benzisoxazoles | ANTIPSYCHOTIC | 73 | 75 | 0.33% | 0.33% | 66 | 93 | 0.31% | 0.21% | \$ 49.13 | \$ 34.90 | -28.95% | |
| 901500 | Antifungals - Topical | TOPICAL ANTIBIOTICS / ANTI-INFECTIVES | 70 | 72 | 0.34% | 0.34% | 99 | 94 | 0.20% | 0.20% | \$ 31.24 | \$ 32.13 | 2.86% | |
| 568520 | Alpha 1-Adrenoceptor Antagonists | BENIGN PROSTATIC HYPERPLASIA | 98 | 90 | 0.22% | 0.26% | 82 | 95 | 0.24% | 0.20% | \$ 57.53 | \$ 42.32 | -26.43% | |
| 568510 | 5-Alpha Reductase Inhibitors | BENIGN PROSTATIC HYPERPLASIA | 149 | 135 | 0.10% | 0.12% | 108 | 96 | 0.17% | 0.20% | \$ 86.74 | \$ 89.44 | 3.11% | |
| 621000 | Smoking Deterrents | SMOKING CESSATION | 147 | 121 | 0.10% | 0.15% | 127 | 97 | 0.13% | 0.20% | \$ 66.68 | \$ 71.04 | 6.54% | |
| 611099 | Amphetamine Mixtures | ATTENTION DEFICIT DISORDER | 167 | 153 | 0.07% | 0.09% | 114 | 98 | 0.15% | 0.20% | \$ 111.04 | \$ 116.22 | 4.66% | |
| 502500 | 5-HT3 Receptor Antagonists | ANTICANCER | 171 | 170 | 0.07% | 0.07% | 88 | 99 | 0.23% | 0.20% | \$ 178.78 | \$ 142.80 | -20.13% | |
| 612540 | Monoamine Reuptake Inhibitors | WEIGHT LOSS | 172 | 173 | 0.07% | 0.07% | 103 | 100 | 0.19% | 0.20% | \$ 147.79 | \$ 153.21 | 3.66% | |
| Top 100 Therapeutic Classes | | | | | | | | | | 86.94% | 86.94% | \$ 62.34 | \$ 62.97 | 1.02% |
| Grand Total (All Therapeutic Classes) | | | | | | | | | | 100% | 100% | \$ 52.57 | \$ 53.30 | 1.40% |

Legend:

Ingredient Cost
GPI
Therapeutic Class Name
Common Indications
Claims Rank
% of Total Claims
Ing Cost Rank
% of Total Ing Cost
Avg Ing Cost/Claim
% Change in Avg Ing Cost/Claim

Ingredient cost allowable including markup before member portion (e.g. fee caps, co-insurance, co-pay, etc.)
Generic Product Indicator: classifies drugs into similar therapeutic classes.
Pharmaceutical name for a specific class of drugs.
Familiar name for conditions treated by a therapeutic class.
The rank of therapeutic classes according to the number of allowable claims.
The percentage of claims within the therapeutic class compared to all therapeutic classes.
The rank of therapeutic classes according to ingredient cost.
The percentage of ingredient cost of the prescriptions within the therapeutic class compared to all therapeutic classes.
Average ingredient cost per claim: the average ingredient cost of all the claims within the therapeutic class.
The percentage of ingredient cost/claim change for the claims within a therapeutic class comparing the two data periods.